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In Germany, IQWIG has proposed to use correlations between surrogate endpoints 
and patient relevant outcomes to determine value of cancer drugs. Due to increased 
cost pressure on payers, such models are likely to inspire novel reimbursement 
schemes for other branded products. ConClusions: Cancer drug reimbursement 
models are setting new benchmark for payers to manage access and control costs. 
These models have significant implications for other expensive branded products.
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The RelaTioNshiP BeTweeN suBmiTTed liNe of TheRaPy aNd 
ReimBuRsemeNT deCisioNs iN solid sTaTe TumoR CaNCeR dRugs
Jao R., Jaksa A., Ho Y.S., Daniel K.
Context Matters, Inc., New York, NY, USA
objeCtives: To explore the relationship between lines of therapy and submission 
for reimbursement across disease conditions and types of therapy. Methods: This 
study looked at 252 Health Technology Assessments from eight agencies: CADTH, 
CCO, HAS, HIS, NICE, PBAC, SMC, and pCODR. The data covered 41 drugs across 
seven solid-state tumor cancer conditions. Results: Of the 41 drugs, 27% (11/41) 
were initially submitted for first-line therapy and 73% (8/11) were recommended 
for reimbursement. Similarly, 32% (13/41) were initially submitted for second-line 
therapy and 77% (10/13) were recommended for reimbursement. Cytotoxic drugs 
were most likely to be reviewed initially for first-line therapy at 35% (7/20) and 
second-line therapy at 25% (5/20); targeted therapies were most likely to be reviewed 
initially for second-line therapy at 38% (8/21) and adjuvant therapy at 24% (5/21). 
The percentage of drugs reviewed for two or more lines of therapy varied greatly 
across conditions. Colorectal Cancer, SCLC, and NSCLC had the greatest percentages 
of drugs reviewed for 2+ lines of therapy with 100% (4/4), 100% (1/1), and 83% (5/6), 
respectively. Melanoma, Prostate Cancer, and Ovarian had the lowest percentages 
with 0% (0/2), 14% (1/7), and 40% (2/5), respectively. Additionally, there was a positive 
correlation (r= 0.9) between the number of drugs reviewed and number of lines of 
therapy covered per disease condition. ConClusions: There was no discernable 
difference in the rate of reimbursement between drugs initially submitted for first-
line therapy or second-line therapy. There were, however, differences in various 
trends across disease conditions and between types of therapy. Future research will 
focus on trends across agencies and will include a larger sample size covering more 
conditions as well as investigational case studies on frequently reviewed drugs.
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objeCtives: To systematically review the currently available clinical and cost-
effectiveness evidence of non-pegylated liposomal doxorubicin (NPLD) for 
non-Hodgkin lymphoma (nHL). The hypothesis under verification was that the 
administration of NPLD lowers the cardiotoxicity typical for conventional anthra-
cyclines while being able to sustain the clinical effect of treatment. Methods: 
A systematic literature search was conducted for clinical and cost-effectiveness 
data for the nHL population treated with NPLD, using the main medical data-
bases (PubMed, EMBASE, Cochrane Library). In addition, clinical trial registries 
were searched, reference lists of included studies and reviews were screened for 
missed studies. Searches took place in September 2012. Results: The review 
generated 9 one-arm clinical trials and 1 retrospective study which met the inclu-
sion criteria. One comparative parallel trial comparing R-CHOP with R-COMP in 
the DLBCL population is ongoing, with no results published. Generally, available 
evidence is poor – studies identified are characterized by many limitations, i.e.: 
small and heterogeneous study populations, relatively short observation period, 
not always specified inclusion and exclusion criteria, diversified treatment regi-
mens (with R-CHOP dominating), shortened or/and presented selectively safety 
data. The majority of studies was performed in the DLBCL population. Cumulative 
interpretation of data was hindered due to essential differences in between trials. 
Lowering of LVEF was observed with a frequency of 0% to 31,7% of cases, while 
symptomatic lowering of LVEF with the development of chronic ischemic heart 
disease occurred with the frequency of 0 to 10%. The second most frequent car-
diological event observed was arrhythmia. Clinical efficacy focused on surrogate 
endpoints (radiological responses), defined differently in between trials. No eco-
nomic evaluations studies were found. ConClusions: There is limited evidence 
on the effectiveness and safety of NPLD in patients with nHL due to the lack of 
well-designed and well-reported comparative studies. Further research is needed 
to explore the hypothesis in question.
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imPaCT of ReCommeNded PhaRmaCeuTiCals oN CaNCeR moRTaliTy: 
aNalysis of Real-life daTa
Wilson T., Hamerslag L.
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objeCtives: To ascertain whether there were any trends in cancer mortality after 
hospital admittance and diagnosis that could be linked to recent approval of thera-
pies by the National Institute for Health and Care Excellence (NICE). Methods: 
Using information provided by Hospital Episode Statistics and the Office of National 
Statistics, yearly mortality data from both the inpatient and outpatient population 
between 2007 and 2010 were extracted. An analysis of 30-, 60-, and 90-day mortal-
ity following admittance to hospital was undertaken for malignancies which had 
seen therapies approved by NICE after 2006. Results: Of the 37 cancer therapies 
assessed by NICE between 2006 and 2010 inclusive, 27 were recommended. Patients 
with lung cancer were found to experience one of the highest mortality rates over-
all. Interestingly, lung cancer also saw the largest number of therapies approved 
between 2006 and 2010 (7), along with a steady decline in the annual 90-day mortal-
ity over the three year period (29.6%, 28.4% and 27.1% in 2007-08, 2008-09 and 2009-
to chemotherapy. The algorithm was validated against a PSA-based definition of 
CRPC (at least two PSA increases following castration or new metastases while 
on hormone therapy). Results: A total of 269 patients met inclusion criteria and 
had 3 or more PSA measurements. The two methods agreed in 88% of patients; 220 
(81.8%) were identified as CRPC by both methods and 17 (6.3%) were identified as not 
castration resistant by both methods. A statistical comparison of the two methods 
yielded a Cohen’s kappa of 0.4491, indicating moderate agreement. ConClusions: 
The algorithm was concordant with a PSA-based definition of CRPC and serves as 
a new tool to identify CRPC patients using claims data. Future validation against a 
different data source is needed.
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imagiNg: desigNiNg BeTTeR CliNiCal TRial PRoToCols
Zowall H., Brewer C., Deutsch A.
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objeCtives: To assess the potential increase in lifetime attributable risk (LAR) 
of cancer incidence due to repeated exposure to medical imaging procedures for 
participants in clinical trials. Methods: Medical imaging in clinical trials has 
grown exponentially in the last decade. We have developed an individual-based 
state-transition model to estimate the LAR of radiation-related cancer following a 
patient’s exposure history, and site-specific dose according to age and gender. Monte 
Carlo simulations to vary effective doses, risk model coefficients, and the period 
for radiation-related cancer latency were performed. Results: We examined two 
scenarios in a three year hypothetical clinical trial: minimal exposure describing 
a subject’s radiation exposure as one abdominal CT scan per year; and frequent 
exposure consisting of five abdominal CT scans per year. For a 30 year old female the 
LAR of cancer incidence increased from 46 per 100,000 population in the minimal 
exposure scenario to 229 per 100,000 in the frequent exposure scenario. For a 30 
year old male, the risk increased from 36 to 179 per 100,000. At age 30, females had 
a 30% higher risk than males, however, cancer incidence at ages 50, and 70 were 
similar for both sexes. At age 50 the LAR of cancer incidence increased from 31 to 
151 per 100,000. At age 70 the risk increased from 15 to 71 per 100,000. The LAR of 
cancer incidence was one third lower in 70 year olds than in 30 year olds, and half 
the rate of 50 year olds. ConClusions: Although the LAR of cancer incidence of a 
single exposure seems to be relatively small, clinical trials that involve a compara-
tively large number of imaging procedures can lead to significantly higher risks. 
Examinations that deliver relatively high doses of radiation, such as CT, need to 
be clinically justified.
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objeCtives: The rising costs of cancer care are a major focus for clinicians, payers 
and patients. This analysis examines trends in bevacizumab chemotherapy admin-
istration and drug reimbursement. Methods: Using the MarketScan© Research 
Databases, administrations of bevacizumab were identified from 1/1/2005 through 
12/31/2012 for patients with commercial or employer-sponsored supplemental 
Medicare insurance. Bevacizumab claims were excluded if the claim had a diagnosis 
related to eye disease or the reimbursed amount was < $100. All claims were iden-
tified as occurring in an office-based setting (OBS), an outpatient hospital setting 
(OHS) or other setting. Results: The percent of bevacizumab claims occurring in OHS 
increased from 6 to 34% among Medicare claims, and from 14 to 42% among commer-
cial claims from 2005 to 2012. Medicare median drug reimbursement was $257 more 
for OHS than OBS in 2005, increasing to a difference of $3,022 in 2009 and declining 
to $1,722 in 2011 before narrowing to $165 in 2012. Medicare median reimbursements 
for chemotherapy administration in OHS were $408 more than OBS in 2005, dropping 
to a difference of $97 in 2008 and ending at $165 in 2012. Commercial differences in 
drug reimbursement for OHS and OBS settings continuously increased from $885 in 
2005 to $3714 in 2011, declining slightly to $3676 in 2012. Differences in chemotherapy 
administration reimbursement were $176 more for OHS than OBS in 2005, the dif-
ference decreasing to $103 in 2007 and increasing to $236 in 2012. ConClusions: 
Although the difference in reimbursements to OHS and OBS has decreased over time 
for Medicare, the differences across settings for commercial insurance increased over 
time with a slight indication that cost increases are slowing. The higher reimburse-
ments in OHS combined with the shift from OBS to OHS over the past 7 years has 
implications for the growth in cancer costs over the past decade.
PCN204
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objeCtives: Cancer drugs are the world’s highest selling category of therapeutic 
products. Due to their premium price and budget impact, several new drug reim-
bursement models have been implemented worldwide by public and private pay-
ers. These models have potential implications for coverage and reimbursement 
of all branded products. This study reviewed recent cancer drug reimbursement 
models and developed lessons and implications for future products. Methods: 
Reviewed cancer drug reimbursement schemes in developed and emerging markets. 
Interviewed payers and KOLs to develop lessons and implications for future prod-
ucts. Results: Public and private payers worldwide have implemented several new 
models for cancer drug reimbursement to manage budgets and control costs. In the 
US, private payers are piloting single source compendia and third party protocols (eg. 
P4 Oncology) to limit off-label use of cancer drugs. In the UK, NICE has successfully 
negotiated lower price and discounts for first few cycles of therapy. In Italy, AIFA has 
implemented registry based patient access for cancer drugs. In India, several manu-
facturers have implemented novel pricing strategy for first few cycles of therapy. 
